Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeuroNova AB

Division of Newron Pharmaceuticals SPA
www.neuronova.com

Latest From Taiho Pharmaceutical Co. Ltd.

Chi-Med Roll Continues With Positive Fruquintinib Phase III Data

Chi-Med's China-focused strategy is paying off with positive Phase III top-line results for its home-grown VEGF inhibitor fruquintinib, keeping it on track to for a filing this year. But competition looms.

Clinical Trials Research & Development

Pipeline Watch: Phase III Success With Emicizumab, Plecanatide And Sotagliflozin

Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.

Pipeline Watch Approvals

Japan Keytruda NSCLC Approval Sets Stage For Opdivo Showdown

Keytruda has been approved in Japan for lung cancer, including first-line use, in a batch of new regulatory clearances that also include the country's first prescription drug for irritable bowel syndrome with constipation.

Japan Approvals

Japan Delays Keytruda Pricing Amid PD-1 Cost Concerns

Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.

Japan Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Newron Pharmaceuticals SPA
  • Senior Management
  • Ulf Ljungberg, PhD, Pres. & CEO
    Henrik Resmark, CFO
    Anders Haegerstrand, MD, PhD, CSO
  • Contact Info
  • NeuroNova AB
    Phone: (46) (0)8 786 0900
    Fiskartorpsvägen 15 A-D
    Stockholm, SE-114 33
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register